JUSTIFICATION OF NITROXOLINE APPLICATION IN CONDITIONS OF GROWTH OF RESISTANCE OF UROPATHOGENES TO NEW GENERATIONS OF ANTIMICROBATES

Author:

Syrota Н. I.,Platonova I. L.

Abstract

Nitroxoline is a synthetic uroantiseptic, effective against a wide range of gram-positive, gram-negative bacteria and fungi. For a long time it has been used for the treatment and prevention of acute, chronic and recurrent urinary tract infections, because to this day retains high activity against bacteria of the family Enterobacteriaceae. With increasing resistance of uropathogens to new antimicrobial drugs, Nitroxoline may be an alternative drug for the treatment of acute uncomplicated urinary tract infections. The results of scientific research on the importance of Nitroxoline as a first-line drug in the treatment of this nosological group of diseases are contradictory. This motivates the study and analysis of the professional literature in the direction of clinical efficacy and determining the place of Nitroxoline among other uroseptics in the treatment of urinary tract infections in today's conditions.

Reference37 articles.

1. Nitroksolin. Instruktsiia. Nakaz MOZ Ukrainy 08.07.2015 № 418. Reiestratsiine posvidchennia № UA/3518/01/01.

2. National Antibiotic Susceptibility Testing Committee (Germany): Nitroxoline. Rationale for the NAK Clinical Breakpoints. [Internet]. URL: https://www.nak-deutschland.org/tl_files/nak-deutschland/Nitroxoline_rationale_V_1.0_31012014.pdf

3. Amgar A. Activity in vitro of urine samples from patients treated by nitroxoline against mycoplasmas. J Chemother. 1989;4:226–8.

4. Hernández Molina JM, Llosá J, Ventosa A. In vitro activity of nitroxoline against clinical isolates of Candida species. Mycoses. 1991;34:823–5.

5. Kresker M, Körber-Irrgang B, on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich society of Chemotherapy: In vitro activity of niroxoline against urine isolates of Echerichia coli from the community: results of a German multicentre study [Abstract]. In 23rd European Congress of Clinical Microbiology and Infections Diseases (23rd ECCMID): 27-30 April 2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3